We hope that GIP and GLP-1 will soon permanently enter the canon of drugs used for CAD-management, also in non-diabetic patients, reducing mortality and the risk of reinfarction or hospitalization for angina pectoris. This evidence concerns the gene GCG and angina pectoris.